+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07570017

Phase Ib Trial of Rocbrutinib Combined With Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Led by Guangzhou Lupeng Pharmaceutical Company LTD. · Updated on 2026-09-10

42

Participants Needed

2

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, preliminary effectiveness, and pharmacokinetics of Rocbrutinib combined with R-GemOx in patients with relapsed or refractory non-GCB diffuse large B-cell lymphoma DLBCL. This phase Ib, multicenter, open-label study includes a dose escalation phase using a classic 33 design to find safe dose combinations, followed by a dose expansion phase based on safety, pharmacokinetics, and initial efficacy data. Participants will receive Rocbrutinib orally once daily at either 150 mg or 200 mg, combined with six 21-day cycles of R-GemOx chemotherapy. R-GemOx includes Rituximab given intravenously on day 1 of each cycle, and Gemcitabine plus Oxaliplatin intravenously on day 2. Treatment with Rocbrutinib continues until disease progression or unacceptable side effects. The study progresses sequentially from dose escalation to expansion based on initial results. Throughout the study, participants undergo assessments including monitoring for dose-limiting toxicities, adverse events, and pharmacokinetics within the first cycle, and tumor response evaluated up to about two years. Safety is assessed from the first dose to 28 days after the last dose. Researchers monitor response rate, time to response, duration of response, progression-free and overall survival, along with drug concentration and metabolism. Participants must provide tissue and blood samples and follow scheduled visits during treatment and follow-up.

CONDITIONS

Brief Title

A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Research Team

Q

Qingqing Cai

R

Rong Tao

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here